Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
allogeneic umbilical cord-derived mononuclear cells
- Development stage
- Unknown
- Lead developer
- Tehran University of Medical Sciences
- Modality
- Stem Cell Therapies → Cell Therapies
- Administration
- Intrathecal
01
Overview
Allogeneic umbilical cord-derived mononuclear cells (UCB-MNCs) are an investigational cell therapy being developed by Tehran University of Medical Sciences for the treatment of spastic cerebral palsy. The therapy involves the intrathecal administration of a heterogeneous population of cells derived from umbilical cord blood, including hematopoietic stem cells, lymphocytes, monocytes, and endothelial progenitor cells. In clinical studies, these cells are evaluated for their ability to improve gross motor function and reduce spasticity in pediatric patients. The therapeutic effect is hypothesized to stem from the paracrine release of neurotrophic and anti-inflammatory factors that promote neural repair and modulate the neuroinflammatory environment associated with brain injury in cerebral palsy.
- Other names
- umbilical cord blood mononuclear cellsallogeneic UCB-MNC
Beyond the preview
Go deeper on allogeneic umbilical cord-derived mononuclear cells.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on allogeneic umbilical cord-derived mononuclear cells.